Finally, after nearly two decades, Exelixis (Nasdaq: EXEL) has received approval from the Food and Drug Administration for its first drug, cabozantinib. Now called Cometriq, it is used to treat advanced medullary thyroid cancer once the disease has spread to other organs. However, in this video, Motley Fool health care analyst David Williamson gives reasons to temper enthusiasm over this approval while keeping an eye on future clinical trial results for cabozantinib in prostate cancer.
Dave Williamson and Brenton Flynn
Nov 30, 2012 at 6:05PM
Motley Fool Returns
Stock Advisor S&P 500
Stock Advisor launched in February of 2002. Returns as of 02/28/2020.Join Stock Advisor
Cumulative Growth of a $10,000 Investment in Stock Advisor Calculated by Time-Weighted Return